2017, Número 3
<< Anterior Siguiente >>
Ann Hepatol 2017; 16 (3)
The Direct-Acting Antivirals for Hepatitis C Virus and the Risk for Hepatocellular Carcinoma
Chinchilla-López P, Qi X, Yoshida EM, Méndez-Sánchez N
Idioma: Ingles.
Referencias bibliográficas: 11
Paginas: 328-330
Archivo PDF: 106.43 Kb.
RESUMEN
Sin resumen.
REFERENCIAS (EN ESTE ARTÍCULO)
Davis G, Albright J, Cook S, Rosenberg D. Projecting Future Complications of Chronic Hepatitis C in the United States. Liver Transplant 2003: 331-8.
Méndez-Sánchez N, Villa A, Chávez-Tapia N, Ponciano-Rodríguez G, Almeda-Valdés P, González D, Uribe M. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005; 1: 52-5.
Yamashita N, Ohho A, Yamasaki A, Kurokawa M, Kotoh K, Kajiwara E. Hepatocarcinogenesis in chronichepatitisCpatientsachievingasustainedvirologicalresponse to interferon: significance of lifelong periodic cancer screening for improving outcomes. J Gastroenterol 2014; 49: 1504-13.
Innes H, McDonald S, Hayes P, Dillon JF, Allen S, Goldberg D2, Mills PR, et al. Mortality in hepatitis C patients who achieve a sustained viral response compared to the generalpopulation. J Hepatol 2017; 1: 19-27.
van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, et al. Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis. JAMA 2012; 24: 2584-93.
Janjua NZ, Chong M, Kuo M, Woods R, Wong J, Yoshida EM, Sherman M, et al. Long-term effect of sustained virological response on hepatocellular carcinoma patients with hepatitis C in Canada. J Hepatol 2017; 66: 504-13.
Camma C, Cabibbo G, Craxi A. Direct antiviral agents and risk for HCC early recurrence: much ado about nothing. J Hepatol 2016; 65: 861-2.
Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with directacting antivirals. J Hepatol 2017 Feb 2. pii: S0168- 8278(17)30053-3. doi: 10.1016/j.jhep.2017.01.020.
Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi F, et al. Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-related Cirrhosis Treated with Direct Acting Antivirals. J Hepatol 2016; 30303-8.
Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, Díaz A, et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 2016; 65: 719-26.
Jacobson I, Lim J, Fried M. Care of Patients Who Have Achieved a Sustained Virologic Response (SVR) Following Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology 2017 doi: 10.1053/j.gastro.2017.03.018.